Neural Therapeutics Inc. (CSE:NURL)

Neural Therapeutics Income Statement

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jan 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022
Selling, General & Admin	0.37	0.37	0.8	0.7
Research & Development	0.16	0.29	0.4	0.04
Operating Expenses	0.53	0.65	1.2	0.74
Operating Income	-0.53	-0.65	-1.2	-0.74
Currency Exchange Gain (Loss)	0	0	-0	0
Other Non Operating Income (Expenses)	-0.02	-0.01	-0	-0
EBT Excluding Unusual Items	-0.55	-0.67	-1.21	-0.74
Other Unusual Items	-	-	0.14	-1.08
Pretax Income	-0.55	-0.67	-1.08	-1.82
Net Income	-0.55	-0.67	-1.08	-1.82
Net Income to Common	-0.55	-0.67	-1.08	-1.82
Shares Outstanding (Basic)	66	63	40	37
Shares Outstanding (Diluted)	66	63	40	37
Shares Change (YoY)	31.99%	58.39%	7.98%	-
EPS (Basic)	-0.01	-0.01	-0.03	-0.05
EPS (Diluted)	-0.01	-0.01	-0.03	-0.05
EBIT	-0.53	-0.65	-1.2	-0.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.